These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA. Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521 [Abstract] [Full Text] [Related]
3. [Results with the use of the M-2 protocol in plasmacytoma]. Ho AD, Wittkamp S, Theml H, Keilholz U, Hunstein W. Dtsch Med Wochenschr; 1986 May 30; 111(22):858-61. PubMed ID: 3754811 [Abstract] [Full Text] [Related]
4. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E. Cancer Treat Rep; 1982 Nov 30; 66(11):1971-3. PubMed ID: 6897205 [Abstract] [Full Text] [Related]
12. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients]. Bladé J, Urbano A, López Guillermo A, Rozman M, Rovira M, Montserrat E, Rozman C. Sangre (Barc); 1990 Apr 30; 35(2):93-7. PubMed ID: 2363100 [Abstract] [Full Text] [Related]
14. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma]. Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H. Rev Rhum Mal Osteoartic; 1984 May 30; 51(5):263-7. PubMed ID: 6740189 [Abstract] [Full Text] [Related]